Effect of Tranexamic Acid (TXA) on Reduction of Postoperative Blood Transfusion

Evaluating the Effect of Tranexamic Acid (TXA) on Reduction of Postoperative Blood Transfusion in Hip Fracture Patients

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT03063892

Enrollment

200

Registered

2017-02-24

Start date

2017-08-30

Completion date

2027-09-01

Last updated

2026-07-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hip Fractures

Brief summary

Tranexamic Acid (TXA) is an antifibrolytic medication used in total hip and knee arthroplasty to reduce the need for intraoperative and postoperative blood transfusions. Limited research is available on its use in hip fracture patients. We hypothesize that the use of TXA preoperatively, perioperatively, and postoperatively will decrease blood loss and need for blood transfusion postoperatively.

Interventions

DRUGTranexamic Acid (TXA)

Tranexamic acid is an antifibrinolytic used to control bleeding

DRUGSaline solution

Saline solution is used as the placebo comparator

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender

ALL

Age

60 Years to No maximum

Healthy volunteers

Inclusion criteria

* Over the age of 60 years * Hip fracture requiring surgical intervention * Signs consent and agrees to participate

Exclusion criteria

* Under the age of 60 * Does not sign consent or refuses participation * Known hypersensitivity to tranexamic acid * Multiple acute fractures * Creatinine clearance \<30 * History of seizures * Active hormone therapy * History of coagulation abnormality * History of deep vein thrombosis (DVT) or pulmonary embolism (PE) within the last year or history or recurrent DVT/PE * Myocardial infarction (MI) and/or stents within the past year * History of intracranial hemorrhage * Acquired defective color vision * Patients admitted directly to nursing units or surgery without stay in the Emergency Center * Patients who sustain fracture while hospitalized at ProMedica Toledo Hospital

Design outcomes

Primary

Measure	Time frame	Description
proportion of patients requiring packed Red Blood Cell transfusion	72 hours	units, perioperative

Secondary

Measure	Time frame	Description
intraoperative blood loss	24 hours	mL
postoperative anemia	72 hours	Hgb \<7g/dL

Countries

United States

Contacts

PRINCIPAL_INVESTIGATORGregory M Georgiadis, MD

ProMedica Toledo Hospital

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Jul 10, 2026